Prolactinomas in the transition from adolescence to young adulthood: A multicentre, retrospective study from the TALENT group
Journal of Neuroendocrinology · 2026-10 · 38 (10)
DOI: 10.1111/jne.70275 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 24.09.2026. Verfasst von Dario De Alcubierre und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Prolactinoma. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-Next Generation EU, Mission 4 Component 2 Investment 1.5, project Rome Technopole.
Abstract (Originalsprache)
Prolactinomas in the transition age present unique challenges; treatment strategies and long‐term outcomes in this population remain incompletely characterised. This is a multicentre, retrospective study of 110 consecutive patients (33 males) with prolactinomas, aged 15–25 years, across five Italian referral centres (2010–2025). Clinical, hormonal, radiological, and treatment‐related parameters were assessed at diagnosis and at follow‐up. At diagnosis, the median age was 20 years; median prolactin 177 ng/mL [49–6646]; 55% of patients had micro‐tumours. Male patients presented with larger tumours, higher prolactin levels, and greater invasiveness ( p < .001 for all comparisons). Cabergoline was first‐line therapy in 95%, achieving prolactin normalisation in 75% and significant tumour shrinkage (≥50% volume and/or diameter reduction) in 66% of patients. Partial resistance (biochemical and/or radiological) occurred in 40% of patients. Treatment discontinuation occurred in 48% of cases; 61% of patients discontinuing cabergoline after prolonged normalisation experienced recurrence, which was predicted by younger age at diagnosis (OR 0.67/year, p = .040) and shorter treatment duration (OR 0.95/month, p = .050), the latter showed 93% sensitivity for recurrence at 45.5 months. Adverse events occurred in 12%, leading to treatment discontinuation in 6%. Surgery was required in 17%, achieving long‐term remission in 31%, while 21% of surgical cases required radiotherapy. At last follow‐up (median 72 months), 73% remained on cabergoline while 25% achieved complete radiological resolution. Transition‐age prolactinomas demonstrate high cabergoline resistance rates and frequent recurrence after discontinuation. Treatment duration ≥45.5 months before withdrawal may reduce recurrence risk. Surgical remission is achievable, especially in non‐invasive tumours, although multimodal therapy is often required for disease control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, Sapienza University, Rome, Italy.
- Neuroendocrinology, IRCCS Neuromed Institute, Pozzilli, Italy.
- Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Clinical Sciences and Community Health, Department of Excellence 2023-2027, University of Milan, Milan, Italy.
- Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Dipartimento Di Medicina Clinica E Chirurgia, Sezione Di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università Federico II Di Napoli, Naples, Italy.
ORCID-Profile: Dario De Alcubierre, Claudia Giavoli, Tiziana Feola, Lorenzo Cerroni, Aurora Pedroli, Giulia Puliani, Rosa Pirchio, Marta Tenuta, Renata S Auriemma, Maria Luisa Appetecchia, Rosario Pivonello, Giovanna Mantovani, Andrea M Isidori, Marie-Lise Jaffrain-Rea, Ashley Grossman
Förderung
- European Union-Next Generation EU, Mission 4 Component 2 Investment 1.5, project Rome Technopole
Zitieren
APA
De Alcubierre, D., Giavoli, C., Feola, T., Cerroni, L., Vincenzi, L., Profka, E., Pedroli, A., Puliani, G., Pirchio, R., Tenuta, M., Auriemma, R. S., Appetecchia, M. L., Pivonello, R., Mantovani, G., Isidori, A. M., Jaffrain-Rea, M. L., Grossman, A., & Sbardella, E. (2026). Prolactinomas in the transition from adolescence to young adulthood: A multicentre, retrospective study from the TALENT group. Journal of Neuroendocrinology, 38(10). https://doi.org/10.1111/jne.70275
Vancouver
De Alcubierre D, Giavoli C, Feola T, Cerroni L, Vincenzi L, Profka E, et al. Prolactinomas in the transition from adolescence to young adulthood: A multicentre, retrospective study from the TALENT group. Journal of Neuroendocrinology. 2026;38(10). doi:10.1111/jne.70275
BibTeX
@article{DeAlcubierre2026,
author = {De Alcubierre, Dario and Giavoli, Claudia and Feola, Tiziana and Cerroni, Lorenzo and Vincenzi, Ludovica and Profka, Eriselda and Pedroli, Aurora and Puliani, Giulia and Pirchio, Rosa and Tenuta, Marta and Auriemma, Renata S and Appetecchia, Maria Luisa and Pivonello, Rosario and Mantovani, Giovanna and Isidori, Andrea M and Jaffrain-Rea, Marie-Lise and Grossman, Ashley and Sbardella, Emilia},
title = {Prolactinomas in the transition from adolescence to young adulthood: A multicentre, retrospective study from the TALENT group},
journal = {Journal of Neuroendocrinology},
year = {2026},
volume = {38},
number = {10},
doi = {10.1111/jne.70275}
}
EUVIMED